Please assess the completion status of the following clinical trial:

Trial Title: Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be platinum sensitive or platinum resistant~* SWOG Performance Status 0-2~* Previously received a platinum and paclitaxel containing regimen~* Projected Life Expectancy of at least 3 months~* Adequate bone marrow function~* Adequate organ function~* Must have received at least 1 prior salvage regimen for recurrent ovarian cancer~* Recovery from acute toxicities from surgery, radiation or chemotherapy~* At least 3 weeks from last therapy~Exclusion Criteria:~* Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact study chair for eligibility~* Second malignancy within last 5 years~* Use of concomitant antioxidants, such as vitamin C or E~* Untreated or symptomatic brain metastases~* History of hypertriglyceride levels \> 200 mg/dl; triglyceride levels \< 200 and receiving treatment are okay.~* Use of certain medications is prohibited - contact study coordinator for information

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fenretinide/LXS + Ketoconozale (Type: EXPERIMENTAL): One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).